Skip to main content

Retatrutide FDA Approval Status

FDA Approved: No
Generic name: retatrutide
Company: Eli Lilly and Company
Treatment for: Weight Loss (Obesity/Overweight)

Last updated by Melisa Puckey, BPharm on Sep 16, 2025.

Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity.

What is the dose of retatrutide?

As it is not an FDA-approved medicine, there is no FDA-approved dose of retatrutide. 

In the Retatrutide Phase 2 clinical trial (NCT04881760):

Experimental weekly dose treatment regimes included:

Disclaimer: dosing outside trials is unsafe and not recommended.

Weight reduction outcomes

The Phase 2 clinical trial demonstrated a dose-dependent reduction in body weight among participants receiving retatrutide. 

Retatrutide weight loss results

Can you get retatrutide yet?

No, retatrutide is only available in clinical trials. It is currently in the development process and is undergoing Phase 3 clinical trials (NCT05882045). As it is not FDA-approved, it is not available in pharmacies or online.

Any products purporting to be retatrutide are not legitimate and are illegal and unsafe. Under federal law, Retatrutide cannot be used in compounded medicines.

FDA-approved obesity medicines include Zepbound (tirzepatide), which is a GIP and GLP-1 receptor agonist, and Wegovy (semaglutide), which is a GLP-1 receptor agonist. There are many other prescription medicines available for this condition.

What are the side effects of retatrutide?

How much will retatrutide cost?

The price has not been announced as it is still in development and is not yet an FDA-approved medicine.

 

Development timeline for retatrutide

DateArticle
Jun 26, 2023Lilly's Phase 2 Retatrutide Results Published in The New England Journal of Medicine Show the Investigational Molecule Achieved up to 17.5% Mean Weight Reduction at 24 weeks in Adults with Obesity and Overweight

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.